The Company is a blank check company whose business purpose is to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. While the Company will not be limited to a particular industry or geographic region in its identification and acquisition of a target company, the Company intends to focus our search on companies in the healthcare industry.
Company profile
Ticker
BLAC, BLACU
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
IRS number
845052822
BLAC stock data
Latest filings (excl ownership)
10-Q
2023 Q2
Quarterly report
14 Aug 23
425
Business combination disclosure
11 Jul 23
8-K
Bellevue Life Sciences Acquisition Corp. and OSR Holdings Sign an Exclusive Letter of Intent for a Business Combination
11 Jul 23
8-K
Entry into a Material Definitive Agreement
28 Jun 23
8-K
Departure of Directors or Certain Officers
14 Jun 23
10-Q
2023 Q1
Quarterly report
22 May 23
NT 10-Q
Notice of late quarterly filing
16 May 23
10-K
2022 FY
Annual report
31 Mar 23
8-K
Bellevue Life Sciences Acquisition Corp. Announces Separate Trading of its Shares of Common Stock, Warrants and Rights Commencing March 17, 2023
14 Mar 23
8-K
Notes to Financial Statement
28 Feb 23
Latest ownership filings
Financial summary
| Quarter (USD) | Jun 23 | Mar 23 | Dec 22 | |
|---|---|---|---|---|
| Revenue | ||||
| Cost of revenue | ||||
| Operating income | ||||
| Operating margin | ||||
| Net income | ||||
| Net profit margin | ||||
| Cash on hand | ||||
| Change in cash | ||||
| Diluted EPS |
| Annual (USD) | Dec 22 | |
|---|---|---|
| Revenue | ||
| Cost of revenue | ||
| Operating income | ||
| Operating margin | ||
| Net income | ||
| Net profit margin | ||
| Cash on hand | ||
| Change in cash | ||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | |||
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 1.18 k | 1.18 k | ||||
| Cash burn (monthly) | 115.87 k | 186.85 k | ||||
| Cash used (since last report) | 334.79 k | 539.85 k | ||||
| Cash remaining | -333.60 k | -538.67 k | ||||
| Runway (months of cash) | -2.9 | -2.9 | ||||
Institutional ownership, Q2 2023
| 13F holders | Current |
|---|---|
| Total holders | 37 |
| Opened positions | 14 |
| Closed positions | 1 |
| Increased positions | 10 |
| Reduced positions | 6 |
| 13F shares | Current |
|---|---|
| Total value | 49.44 bn |
| Total shares | 12.12 mm |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| Polar Asset Management Partners | 1.08 mm | $3.79 bn |
| Boothbay Fund Management | 933.12 k | $6.44 bn |
| Atw Spac Management | 933.12 k | $3.28 bn |
| Rivernorth Capital Management | 750.00 k | $2.63 bn |
| Saba Capital Management | 750.00 k | $2.63 bn |
| Highbridge Capital Management | 736.47 k | $169.39 mm |
| Periscope Capital | 670.45 k | $363.78 mm |
| Exos TFP | 600.00 k | $2.11 bn |
| Spartan Fund Management | 600.00 k | $2.11 bn |
| D. E. Shaw & Co. | 450.00 k | $1.59 bn |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 23 Mar 23 | Bellevue Global Life Science Investors | Common Stock | Other | Dispose J | No | No | 0 | 20,000 | 0.00 | 2,000,500 |
| 23 Mar 23 | Bellevue Global Life Science Investors | Warrant for Common Stock Common Stock | Other | Dispose J | No | No | 11.5 | 20,000 | 230.00 k | 370,000 |
| 23 Mar 23 | David Jin Yoo | Common Stock | Grant | Acquire A | No | No | 0 | 20,000 | 0.00 | 20,000 |
| 23 Mar 23 | David Jin Yoo | Warrant for Common Stock Common Stock | Grant | Acquire A | No | No | 11.5 | 20,000 | 230.00 k | 20,000 |
| 23 Mar 23 | Kuk Hyoun Hwang | Common Stock | Other | Dispose J | Yes | No | 0 | 20,000 | 0.00 | 2,000,500 |
| 23 Mar 23 | Kuk Hyoun Hwang | Warrant for Common Stock Common Stock | Other | Dispose J | Yes | No | 11.5 | 20,000 | 230.00 k | 370,000 |
| 21 Feb 23 | Kuk Hyoun Hwang | Common Stock | Other | Dispose J | Yes | No | 0 | 4,500 | 0.00 | 2,020,500 |
| 21 Feb 23 | Kuk Hyoun Hwang | Common Stock | Other | Acquire J | Yes | No | 0 | 225,000 | 0.00 | 2,025,000 |
| 21 Feb 23 | Bellevue Global Life Science Investors | Common Stock | Other | Dispose J | No | No | 0 | 4,500 | 0.00 | 2,020,500 |
| 21 Feb 23 | Bellevue Global Life Science Investors | Common Stock | Other | Acquire J | No | No | 0 | 225,000 | 0.00 | 2,025,000 |